BlackRock Global Funds - World Healthscience Fund D5 GBP Inc

Category Sector Equity Healthcare

star-filledstar-filledstar-filledstar-filledstar-filled
This fund can be held in an Investment ISA, SIPP and Investment Account
Last buy/sell price

£14.21

arrow-up£0.06 (+0.42%)

Fund Code

BGWDI

BK6KTX9

LU2112292763

Prices updated as at 14 Mar 2025
|
Prices in GBP

Investment objective
The Fund seeks to maximise total return and invest in a manner consistent with the principles of environmental, social and governance (“ESG”) investing. The Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed.

Important notice: This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements for retail clients.

Company name
BlackRock (Luxembourg) SA
Fund launch date
06 Apr 2001
Domicile
Luxembourg
UCITS
Yes
Fund manager
Erin Xie
Manager start date
01 Apr 2011
Fund manager biography
Erin Xie, PhD, Managing Director and portfolio manager, is the head of the Health Sciences team, part of BlackRock’s Active Equity Group. She is the lead portfolio manager for the Health Sciences equity portfolios. Ms. Xie's service with the firm dates back to 2001, including her years with State Street Research & Management (SSRM), which merged with BlackRock in 2005. At SSRM, she was a Senior Vice President and portfolio manager responsible for managing the State Street Health Sciences Fund. Prior to joining State Street Research in 2001, Ms. Xie was a research associate with Sanford Bernstein covering the pharmaceutical industry from 1999. From 1994 until 1997, she was a post doctoral research scientist at Columbia University. Ms. Xie earned a BS degree in chemistry from Beijing University in 1988, a PhD degree in Biochemistry from the University of California, Los Angeles, in 1993 and a MBA degree from the Massachusetts Institute of Technology Sloan School of Management in 1999.
Fund manager
Xiang Liu
Manager start date
01 Jun 2020
Fund manager biography
Xiang Liu, PhD, Director, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the medical devices & supplies sector. Prior to joining BlackRock in 2008, Mr. Liu was a partner and biotech analyst at Mehta Partners. From 2002 to 2005, he was a Director in the corporate development department at Cubist Pharmaceuticals. Mr. Liu began his investment career in 2000 at the Boston Consulting Group as a Healthcare consultant. Mr. Liu earned a BS degree in Chemistry from the University of Science & Technology, China in 1993, a PhD degree in Chemistry from Yale University in 1997, and a MBA degree in finance, strategy, and accounting from the University of Chicago in 2000.
Head office
35 A, avenue J.F. Kennedy,
Luxembourg
Luxembourg
L-1855
Got a question?
Get in touch
we're here to help:
+44 20 77433000
Mon-Fri 8am to 6pm


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.


Any ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
© Copyright 2025 Morningstar. All rights reserved.